Acutus Medical, Inc. (NASDAQ:AFIB – Get Rating) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,690,000 shares, a growth of 30.0% from the March 31st total of 1,300,000 shares. Approximately 7.7% of the shares of the company are short sold. Based on an average daily volume of 525,100 shares, the days-to-cover ratio is presently 3.2 days.
Shares of AFIB opened at $1.28 on Monday. The business’s 50-day moving average price is $1.44 and its 200 day moving average price is $3.13. The stock has a market capitalization of $36.20 million, a P/E ratio of -0.31 and a beta of 2.66. Acutus Medical has a 1-year low of $0.76 and a 1-year high of $18.00. The company has a current ratio of 6.82, a quick ratio of 5.94 and a debt-to-equity ratio of 0.38.
Acutus Medical (NASDAQ:AFIB – Get Rating) last released its earnings results on Wednesday, March 30th. The company reported ($1.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.21). The business had revenue of $4.36 million for the quarter, compared to analysts’ expectations of $4.30 million. Acutus Medical had a negative net margin of 681.71% and a negative return on equity of 116.28%. On average, research analysts predict that Acutus Medical will post -3.17 earnings per share for the current year.
Several equities analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Acutus Medical from a “hold” rating to a “sell” rating in a report on Monday, April 4th. BTIG Research raised shares of Acutus Medical from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 27th. William Blair restated a “market perform” rating on shares of Acutus Medical in a research report on Thursday, March 31st. UBS Group cut shares of Acutus Medical from a “buy” rating to a “hold” rating in a research note on Friday, January 14th. Finally, Canaccord Genuity Group decreased their price objective on shares of Acutus Medical from $10.00 to $3.00 and set a “hold” rating on the stock in a research report on Friday, January 14th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.60.
Acutus Medical Company Profile (Get Rating)
Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.
- Get a free copy of the StockNews.com research report on Acutus Medical (AFIB)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.